Efficacy of Dupilumab in Chronic Spontaneous Urticaria Supported by Phase 3 Study Results
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the phase 3 LIBERTY-CUPID Study C trial for dupilumab (Dupixent) in chronic spontaneous urticaria (CSU) successfully met i...
Read →